Quantcast
Last updated on April 23, 2014 at 20:01 EDT

Latest Oncolytic virus Stories

New Weapons In The Fight Against Canine Cancer
2012-09-11 10:31:42

April Flowers for redOrbit.com - Your Universe Online Two recent studies have shown real progress in killing cancer cells in dogs. The first study, from the University of Illinois at Urbana-Champaign, reports that myxoma, a pox virus that affects rabbits but not humans, dogs or other vertebrates studied so far, infects several different types of canine cancer cells in cell culture while sparing healthy cells. The study adds to the evidence that viruses or modified viruses will emerge as...

2012-09-07 11:07:28

School of Medicine discovery is proving effective in overseas trials RSV, a virus that causes respiratory infections in infants and young children, selectively kills cancer cells while leaving healthy cells alone, researchers from the School of Medicine at The University of Texas Health Science Center San Antonio said. Santanu Bose, Ph.D., of the School of Medicine, is the inventor on a pending U.S. patent of RSV as an oncolytic therapy. This represents a new use for the virus. Bandana...

2012-07-25 02:29:12

SAN FRANCISCO, July 25, 2012 /PRNewswire/ -- Jennerex, Inc., a private, clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic immunotherapies, today announced that the first patient has been treated in a Phase 2 clinical trial of intravenous treatment with JX-594 for patients with advanced hepatocellular carcinoma (HCC), or liver cancer, who have not received treatment with sorafenib--the current standard of...

2012-07-05 02:23:55

HELSINKI, Finland, July 5, 2012 /PRNewswire/ -- Oncos Therapeutics, the biotech company executing a clinical development program on its next generation oncolytic viruses, today announced the appointment of its Clinical Advisory Board (CAB). Bringing together a group of recognized leading experts in Oncology and Oncolytic Virus drug development, combining a wealth of clinical, strategic, and scientific experience in cancer drug development, immunotherapy, and oncolytic viruses,...

2012-06-28 02:27:43

SAN FRANCISCO, June 28, 2012 /PRNewswire/ -- Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic immunotherapy products for cancer, today announced that Laurent Fischer, M.D., has been appointed to the positions of president, chief executive officer and board member. He succeeds interim CEO, Ken Newport, who will continue in his role as a board member of the company. Dr. Fischer brings 20...

Common Cold Virus Can Possibly Fight Cancer
2012-06-15 06:10:12

Connie K. Ho for redOrbit.com Researchers from Leeds University and the Institute of Cancer Research (ICR) recently announced that they discovered how a common cold virus could be beneficial in eliminating tumors and jump starting an immune response when injected into the blood stream. This new finding could have an impact on the creation of new forms of cancer treatments. Reoviruses are thought to cause stomach pains and colds in children. However, according to Reuters Health, the...

2012-06-13 10:23:48

CALGARY, June 13, 2012 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that a paper entitled "Cell Carriage, Delivery, and Selective Replication of an Oncolytic Virus in Tumor in Patients," has been published in the latest issue of the journal Science Translational Medicine (Vol. 4 Issue 138 138ra77). The paper covers findings from a U.K. translational clinical trial (REO 013) investigating intravenous administration of REOLYSIN in...

2012-06-13 14:50:35

A team of researchers at Lawson Health Research Institute and Western University have identified a novel way that a common virus, called adenovirus, causes disease. In doing so, they have discovered important information on one of the body's key immune responses. Their findings, published today in Cell Host & Microbe, may have implications for infectious diseases and cancer. Adenovirus infections most often cause mild illnesses of the respiratory system, resulting in runny noses,...

2012-06-04 02:25:26

CHICAGO, June 4, 2012 /PRNewswire/ -- Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic virus products for cancer, today announced that data relating to the company's oncolytic virus therapy for cancer was featured in three separate abstracts during the American Society of Clinical Oncology (ASCO) Annual Meeting currently taking place in Chicago, Illinois. Abstract #TPS4152: Jennerex...

2012-05-28 22:20:44

HELSINKI, Finland, May 29, 2012 /PRNewswire/ -- Oncos Therapeutics today announced the successful initiation of its Phase I clinical study of CGTG-102, an oncolytic adenovirus suggested as a potential new treatment for many types of solid tumors. The first patients have already completed the safety assessment part of the study. "We are proud to be the first clinic in Northern Europe to start a clinical study with oncolytic viruses," comments the Principal Investigator of...